DTwP-HB-Hib: Antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old

Hartono Gunardi, Kusnandi Rusmil, Eddy Fadlyana, Meita Dhamayanti, Rini Sekartini, Rodman Tarigan, Hindra Irawan Satari, Bernie Endyarni Medise, Rini Mulia Sari, Novilia Sjafri Bachtiar, Cissy B. Kartasasmita, Sri Rezeki S. Hadinegoro

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background: The new combination of DTwP-HB-Hib vaccines has been developed in Indonesia following World Health Organization (WHO) recommendation and integrated into national immunization program. The aims of the study were to measure 1) antibody persistence 12-18 months after a primary series, 2) immune response and safety after a booster dose of DTwP-HB-Hib. Methods: This was a multi-center, open-labeled, prospective, interventional study. Subjects who had received complete primary dose of DTwP-HB-Hib vaccine from the previous phase III trial were recruited in this trial. Subjects were given one dose of DTwP-HB-Hib (Pentabio®) booster at age 18-24 months old. Diphtheria, tetanus, pertussis, hepatitis B, Hemophilus influenza type B antibodies were measured before and after booster to determine antibody persistence and immune response. Vaccine adverse events were assessed immediately and monitored until 28 days after the booster recorded with parent's diary cards. Results: There were 396 subjects who completed the study. Increased proportion of seroprotected subjects from pre-booster to post-booster were noted in all vaccine antigens: 74.5 to 99.7% for diphtheria; 100 to 100% for tetanus; 40.4 to 95.5% for pertussis; 90.2 to 99.5% for hepatitis B; and 97.7 to 100% for Hib. Common systemic adverse events (AEs) were irritability (23.7-25%) and fever (39.9-45.2%). Local AEs such as redness, swelling, and induration were significantly less common in the thigh group (7.7, 11.3, and 7.1%) than in the deltoid group (28.9, 30.7, and 25%) (P<0.001). Most AEs were mild and resolved spontaneously within three-day follow-up period. Conclusions: Booster of DTwP-HB-Hib vaccine at age 18-24 months is required to achieve and maintain optimal protective antibody. The vaccine is safe and immunogenic to be used for booster vaccination.

Original languageEnglish
Article number177
JournalBMC Pediatrics
Issue number1
Publication statusPublished - 28 May 2018


  • Booster dose
  • Children
  • DTwP-HB-Hib vaccine
  • Immunogenicity
  • Safety


Dive into the research topics of 'DTwP-HB-Hib: Antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old'. Together they form a unique fingerprint.

Cite this